Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials
Journal of the American College of Cardiology, Volume 63, No. 13, Year 2014
Notification
URL copied to clipboard!
Description
Objectives The purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp)(a) from a pooled analysis of 4 phase II trials. Background Lp(a), a low-density lipoprotein (LDL) particle linked to the plasminogen-like glycoprotein apolipoprotein(a), shows a consistent and independent positive association with cardiovascular disease risk in epidemiological studies. Current therapeutic options to reduce Lp(a) are limited. Methods A pooled analysis of data from 1,359 patients in 4 phase II trials assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relationship between Lp(a) and lowering of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, and the influence of background statin therapy. Lp(a) was measured using a standardized isoform-independent method. Results Evolocumab treatment for 12 weeks resulted in significant (p < 0.001) mean (95% confidence interval) dose-related reductions in Lp(a) compared to control: 29.5% (23.3% to 35.7%) and 24.5% (20.4% to 28.7%) with 140 mg and 420 mg, dosed every 2 and 4 weeks, respectively, with no plateau of effect. Lp(a) reductions were significantly correlated with percentages of reductions in LDL-C (Spearman correlation coefficient, 0.5134; p < 0.001) and apolipoprotein B (Spearman correlation coefficient, 0.5203; p < 0. 001). Mean percentage reductions did not differ based on age or sex but the trend was greater in those patients taking statins. Conclusions Inhibition of PCSK9 with evolocumab resulted in significant dose-related reductions in Lp(a). While the mean percentage of reduction was significantly greater in those patients with baseline Lp(a) of ≤ 125 nmol/l, the absolute reduction was substantially larger in those with levels >125 nmol/l. © 2014 by the American College of Cardiology Foundation.
Authors & Co-Authors
Raal, Frederick Johan
South Africa, Johannesburg
University of the Witwatersrand
Giugliano, Robert P.
United States, Boston
Brigham and Women's Hospital
Sabatine, Marc S.
United States, Boston
Brigham and Women's Hospital
Koreň, Michael J.
United States, Jacksonville
Jacksonville Center for Clinical Research
Langslet, Gisle
Norway, Oslo
Oslo Universitetssykehus
Bays, Harold Edward
United States, Louisville
Louisville Metabolic and Atherosclerosis Research Center
Blom, Dirk J.
South Africa, Cape Town
University of Cape Town
Eriksson, Mats
Sweden, Stockholm
Karolinska Universitetssjukhuset
Dent, Ricardo
United States, Thousand Oaks
Amgen Incorporated
Wasserman, Scott M.
United States, Thousand Oaks
Amgen Incorporated
Huang, Fannie
United States, Thousand Oaks
Amgen Incorporated
Xue, Allen
United States, Thousand Oaks
Amgen Incorporated
Albizem, Moetaz
United States, Thousand Oaks
Amgen Incorporated
Scott, Robert A.
United States, Thousand Oaks
Amgen Incorporated
Stein, Evan A.
United States, Chicago
Evlin Consultants
Statistics
Citations: 333
Authors: 15
Affiliations: 9
Identifiers
Doi:
10.1016/j.jacc.2014.01.006
ISSN:
07351097
e-ISSN:
15583597
Research Areas
Noncommunicable Diseases